Goodwin Biotechnology, Inc. has recently expanded its Bioconjugation capabilities by adding a dedicated suite for developing and manufacturing cytotoxic Antibody Drug Conjugates (ADCs) up to Safebridge level 4/5. “For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development and GMP manufacturing of a broad portfolio of  ADC projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody-Peptide Conjugates, Antibody-Dye Conjugates, PEGylated protei...